acrin gynecologic committee
Download
Skip this Video
Download Presentation
ACRIN Gynecologic Committee

Loading in 2 Seconds...

play fullscreen
1 / 26

ACRIN Gynecologic Committee - PowerPoint PPT Presentation


  • 185 Views
  • Uploaded on

ACRIN Gynecologic Committee. Fall Meeting 2010. ACRIN 6695.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'ACRIN Gynecologic Committee' - aspen


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
acrin 6695
ACRIN 6695

Perfusion CT (DCE-CT) as an early predictor of response to combined cytotoxic and anti-angiogenic chemotherapy and as a surrogate marker of long-term outcome for patients with advanced stage epithelial ovarian, peritoneal and fallopian tube cancer: A companion study to GOG 262

Chaan Ng

background biomarkers

Overall survival

  • Response
  • Biomarkers in oncology
    • -Assessment of tumor response
    • -Predictors of response
    • -Prognostic markers
  • CEA, PSA, Ca125
  • TNM
  • RECIST

BACKGROUND: Biomarkers

background ct perfusion
BACKGROUND: CT Perfusion
  • CT Perfusion
    • Tissue viability
      • Angiogenesis
    • Functional evaluation
      • Tumor blood flow, volume, permeability
    • Combined with routine CT staging
background the question
BACKGROUND: “THE QUESTION”
  • Utility of CT perfusion in oncology
  • Translatability of CT perfusion into clinical environment
background the study
BACKGROUND: THE STUDY
  • ACRIN 6695
  • GOG 262
slide9

“Conventional”

“Dose-dense”

•Primary Endpoint:

-Progression-free survival (PFS)

•Secondary Endpoints:

-Overall Survival (OS)

-Response Rate (RR)

-Toxicity

-Translational Research -Quality of Life

imaging objectives primary
IMAGING OBJECTIVES: Primary
  • Whether larger changes in tumor perfusion parameters (T2 - T0) are predictive of better progression-free-survival rate at 6 months (PFS6m)
    • [Early predictorof response?]
    • [Prior to first routine CT restaging]
target lesion
TARGET LESION
  • Precontrast
    • >1cm short axis
    • > 10 HU on pre-contrast (50% of lesion)
  • Postcontrast
    • > 5 HU enhancement (in 50% of lesion)
ct contrast
CT CONTRAST
  • Oral contrast
    • Negative or positive contrast
  • IV contrast
    • >300 mgI2/mL
    • 3-4 mL/s
    • 0.8 mL/kg body weight (max. 70 mL volume)
target lesion19
TARGET LESION
  • > 2cm
  • Round or oval
    • Not plaques
  • Avoid motion
    • Retroperitoneum
    • Pelvis
  • Enhancement
    • Cyst, ascites, hematoma
  • Postop changes
eligibility
ELIGIBILITY
  • Eligible for GOG
  • Adequate renal function
  • No contraindication to IV contrast medium
  • Diabetics on Metformin
  • Consent process
    • Correlative within Consent Form of participating GOG sites, with “opt-out”
analyses
ANALYSES
  • Central perfusion CT data analysis
    • Ting Lee
    • ACRIN HQ
  • Data available for alternative analyses
    • GE model
    • Other vendors
accrual
ACCRUAL
  • ACRIN = 70 evaluable
    • GOG = 625
  • Attrition
    • In practice we need 25-30% of GOG accrual
challenges
CHALLENGES
  • Accrual
    • Sites
    • GOG
    • Target lesions
  • Radiationdose
sites
SITES
  • Looking for collaborating sites
contact details
CONTACT DETAILS
  • Chaan Ng
    • Department of Radiology
    • MD Anderson Cancer Center
    • Houston, TX 77030-4009
    • Phone: 713-792-6759
    • Email:[email protected]
  • Ting-Yim Lee
    • Imaging Research Labs,
    • Robarts Research Institute
    • London, Ontario, Canada
    • Phone: 519-663-5777 ext. 24131
    • Email: [email protected]
ad